A. Spira

Alona Muzikansky, Thomas J Lynch, Bruce E Johnson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors

P. Jänne, L. Sequist, T. Lynch, 2007 .

Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

A. Chiang, L. Hart, M. Pietanza, 2015 .

Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR)

Keunchil Park, J. Yi, J. Mazières, 2016, Pneumologie.

Title : A Phase 1b Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

M. Erlander, S. Silberman, G. Schiller, 2020 .

Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement

Edward S. Kim, R. Schilsky, Caroline Schenkel, 2021, Clinical Cancer Research.

Extensive-stage small-cell lung cancer.

D. Ettinger, A. Spira, 2003, Seminars in surgical oncology.

Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.

J. Radford, S. Horwitz, J. Wuerthner, 2021, The Lancet. Haematology.

A. Gnanasakthy, Xiaolei Zhou, J. Radford, 2021, Clinical lymphoma, myeloma & leukemia.

Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups

M. Socinski, J. Mazières, D. Shames, 2018, Clinical Trials.

Incidence of Neuregulin1 (NRG1) gene fusions across tumor types.

Edward S. Kim, J. Nieva, A. Wozniak, 2018 .

Product review on the Anti-PD-L1 antibody atezolizumab

A. Spira, Stephen V. Liu, Karin Choquette, 2018, Human vaccines & immunotherapeutics.

Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-pretreated advanced NSCLC patients.

A. Wozniak, E. Felip, J. Chaft, 2018 .

1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

C. Blakely, D. Waterhouse, E. Garon, 2021, Annals of Oncology.

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.

D. Planchard, C. Faivre-Finn, S. Senan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

A. Drilon, M. Burkard, Melissa L. Johnson, 2019, Journal of Thoracic Oncology.

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Matthew J. Davis, R. Yelensky, D. Carbone, 2022, Nature Medicine.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

M. Suarez‐Almazor, M. Atkins, M. Anadkat, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

D. Smith, E. Small, R. Kurzrock, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A

A. Spira, S. Klempner, J. Chao, 2022, ESMO open.

Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5)

C. Dooms, M. Socinski, J. Riess, 2021, Clinical Trials.

Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.

G. Shapiro, P. Schőffski, A. Daud, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tecemotide ( L-BLP 25 ) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer ( START ) : a randomised , double-blind , phase 3 trial

M. Socinski, F. Shepherd, R. Ramlau, 2013 .

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

M. Socinski, F. Shepherd, R. Ramlau, 2014, The Lancet. Oncology.

Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts

Infante, K. Sikorska, M. Sznol, 2020, Journal of Translational Medicine.

EP1.12-06 New Treatment Option for ES-SCLC: Patient Characteristics and Use of an Atezolizumab Regimen in the Real-World Setting

A. Mansfield, T. Mekhail, F. Braiteh, 2019, Journal of Thoracic Oncology.

Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.

Jie Yang, C. Gridelli, M. Ahn, 2022, Clinical lung cancer.

Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.

Michael N. Alonso, E. Perez, D. Rasco, 2021 .

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.

A. Drilon, Y. Ohe, J. Wolf, 2022, The Lancet. Oncology.

Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.

A. Italiano, K. Yoh, M. Millward, 2021, Cancer treatment and research communications.

LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation

J. Christensen, S. Ou, R. Yaeger, 2021, Annals of Oncology.

A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS).

Robin L. Jones, G. Demetri, H. Tawbi, 2015 .

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Robin L. Jones, G. Demetri, H. Tawbi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcome of single agent volasertib (BI 6727) as second-line treatment of patients (pts) with advanced or metastatic urothelial cancer (UC).

G. Sonpavde, M. Ernstoff, M. Carducci, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

R. Larson, G. Martinelli, J. Cortes, 2016 .

Results of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophagel junction adenocarcinoma: Results of a randomized phase II study.

A. Spira, D. Richards, L. Asmar, 2011, Journal of Clinical Oncology.

Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

A. Goldberg, M. Tallman, W. Stock, 2020, Leukemia research.

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer.

D. Planchard, C. Faivre-Finn, S. Senan, 2021, Future oncology.

Brigatinib versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.

Jie Yang, S. Gettinger, M. Ahn, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer

R. Govindan, A. Mansfield, Y. Lou, 2021, Clinical Cancer Research.

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non–Small Cell Lung Cancer A C

R. Govindan, Y. Lou, N. Gabrail, 2021 .

Safety and activity of the pan–fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma

J. Blay, P. Hammerman, A. Italiano, 2016 .

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

M. Hurwitz, M. Sznol, I. Puzanov, 2021, Journal of Clinical Oncology.

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

R. Heist, K. Kelly, E. Vokes, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).

R. Govindan, J. Ahn, S. Ou, 2015 .

Dicentric (17;20)(p11.2;q11.2): an uncommon cytogenetic abnormality in myeloid malignancies.

J. Butera, L. Glasser, A. Spira, 2006, Cancer Genetics and Cytogenetics.

Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A.

P. Hegde, I. Wistuba, F. Hirsch, 2015 .

Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma

R. Figlin, I. Henderson, J. Stephenson, 2008 .

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer

C. Borel, P. A. Rolfe, C. Ihling, 2022, Frontiers in Oncology.

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial.

Edward J. Kim, H. Lenz, S. Kopetz, 2018 .

Efficacy and Safety Results of the Afatinib Expanded Access Program

Edward S. Kim, B. Halmos, A. Spira, 2017, Oncology and Therapy.

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

P. Jänne, R. Heist, J. Christensen, 2022, The New England journal of medicine.

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer

Jie Yang, P. Jänne, Gregory Riely, 2022, Expert review of anticancer therapy.

Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer

C. Gridelli, S. Gettinger, M. Ahn, 2018, The New England journal of medicine.

Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study

R. Larson, G. Martinelli, J. Cortes, 2017, The Lancet. Oncology.

A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

C. Rudin, A. Jimeno, J. Bauman, 2015, Oral oncology.

Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques

A I Spira, D. Ho, Steven Wolinsky, 1996, The Journal of experimental medicine.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Keunchil Park, J. Yi, J. Mazières, 2016, The Lancet.

Efficacy/safety of epacadostat plus pembrolizumab in triple-negative breast cancer and ovarian cancer: Phase I/II ECHO-202 study.

David C. Smith, E. Schmidt, V. Borges, 2017 .

Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion.

A. Iafrate, A. Drilon, M. Mino‐Kenudson, 2017, JCO precision oncology.

Progesterone implants enhance SIV vaginal transmission and early virus load

D. Ho, A. Gettie, A. Lackner, 1996, Nature Medicine.

Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.

J. Neal, Gregory Riely, D. Costa, 2021, Cancer discovery.

Signature program: a platform of basket trials

D. Berry, S. Stein, F. Meric-Bernstam, 2018, Oncotarget.

A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer.

R. Plummer, C. Redfern, G. Shapiro, 2021, Lung cancer.

Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001).

A. Drilon, Y. Ohe, B. Konda, 2022, Journal of Clinical Oncology.

A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer

H. Cottrill, J. Trepel, B. Oronsky, 2017, Medical Oncology.

Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).

M. Socinski, E. Smit, V. Lee, 2021, Journal of Clinical Oncology.

1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC

E. Cho, J. Infante, B. Cho, 2020 .

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

S. Ou, Keunchil Park, E. Cho, 2021 .

Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.

B. Cho, A. Spira, S. Vijayaraghavan, 2022, Clinical lung cancer.

Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy.

F. Hirsch, P. Bunn, M. Varella‐Garcia, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.

E. Schmidt, A. Balmanoukian, S. Patel, 2017 .

Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037.

David C. Smith, E. Schmidt, A. Balmanoukian, 2017 .

Cell‐Free DNA Next‐Generation Sequencing Prediction of Response and Resistance to Third‐Generation EGFR Inhibitor

E. Helman, R. Camidge, T. Harding, 2018, Clinical lung cancer.

Abstract CT224: Phase Ib/II, open label, multicenter study of inhaled DV281, a Toll-like receptor 9 agonist, in combination with nivolumab in patients with advanced or metastatic non small cell lung cancer (NSCLC)

R. Coffman, R. Janssen, Melissa L. Johnson, 2019, Clinical Trials.

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

G. Hampton, P. Hegde, I. Wistuba, 2018, Proceedings of the National Academy of Sciences.

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer

C. Rudin, J. Nemunaitis, B. Halmos, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

M. Erlander, S. Silberman, G. Schiller, 2020, Clinical Cancer Research.

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.

J. Christensen, Melissa L. Johnson, R. Yaeger, 2022, Journal of Clinical Oncology.

First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer

A. Mansfield, P. LoRusso, R. Nanda, 2021, Investigational New Drugs.

Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.

C. Iacobuzio-Donahue, A. Jimeno, M. Hidalgo, 2010, Clinical colorectal cancer.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

R. Govindan, J. Ahn, S. Ou, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in the US Oncology Network biomarker testing in metastatic NSCLC with first-line therapy.

N. Robert, R. Coleman, M. Karhade, 2022, Lung cancer.

Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors

J. Berlin, Hulin Jin, C. Robinson, 2022, Investigational New Drugs.

Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2020 .

Yeast structural gene (APN1) for the major apurinic endonuclease: homology to Escherichia coli endonuclease IV.

Arlen W. Johnson, S C Popoff, A I Spira, 1990, Proceedings of the National Academy of Sciences of the United States of America.

10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

H. Wakelee, L. Sequist, S. Ou, 2014 .

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial

Edward J. Kim, H. Lenz, S. Kopetz, 2022, The oncologist.

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.

A. Jimeno, E. Winquist, R. Cohen, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

M. Socinski, F. Shepherd, R. Ramlau, 2013 .

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.

C. Paweletz, J. Christensen, S. Ou, 2022, The New England journal of medicine.

KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.

T. Mok, E. Felip, S. Dakhil, 2021 .

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

P. Jänne, S. Ou, R. Heist, 2021 .

The use of chemotherapy in soft-tissue sarcomas.

D. Ettinger, A. Spira, 2002, The oncologist.

A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.

S. Aggarwal, J. Gray, A. Spira, 2021, Lung cancer.

A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer.

T. Bekaii-Saab, E. Kwak, S. Mikhail, 2016 .

Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer

A. Spira, K. Marrone, M. Guo, 2021, Cancer journal.

OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients

G. Hampton, P. Hegde, G. Frampton, 2017 .

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First‐Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

D. Spigel, D. Waterhouse, E. Garon, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Jie Yang, S. Gettinger, M. Ahn, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non–small Cell Lung Cancer

R. Coffman, Melissa L. Johnson, L. Bazhenova, 2021, Clinical Cancer Research.

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

G. Demetri, P. Sharma, A. Tolcher, 2021, Clinical Cancer Research.

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

A. Tolcher, A. Italiano, M. Tanner, 2020, Clinical and translational science.

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

R. Govindan, A. Italiano, J. Tabernero, 2019, Clinical Cancer Research.

Effect of different donor cells on human immunodeficiency virus type 1 replication and selection in vitro

D. Ho, A. Spira, 1995, Journal of virology.

Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.

A. Mansfield, S. Ou, R. Salgia, 2022, Journal of Clinical Oncology.

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

P. LoRusso, P. Ott, J. Bendell, 2021, Journal for ImmunoTherapy of Cancer.

Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma

S. Horwitz, J. Wuerthner, J. Boni, 2018, Blood.

Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.

Melissa L. Johnson, K. Papadopoulos, Sang-We Kim, 2021 .

Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib

Melissa L. Johnson, L. Bazhenova, Jun Zhang, 2023, The oncologist.

Adagrasib safe and clinically active in non-small cell lung cancer

A. Spira, Robert van den Heuvel, 2022, Medicom Conference Report ASCO 2022.

Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.

M. Ahn, D. Camidge, Geoffrey Liu, 2020 .

Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.

E. Petricoin, L. Liotta, E. Petricoin, 2014, Journal of proteome research.

OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC

T. Burns, A. Spira, A. Chiappori, 2022, Journal of Thoracic Oncology.

Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer

Edward S. Kim, M. Socinski, Chul Kim, 2021, Molecular Cancer Therapeutics.

Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in KRAS p.G12C mutated non-small cell lung cancer (NSCLC).

C. Dooms, G. Shapiro, F. Barlesi, 2021 .

Clinical outcomes and resource utilization after surgical resection with curative intent among patients with non‐small cell lung cancer treated with adjuvant therapies in a community oncology setting: A real‐world retrospective observational study

A. Spira, B. Cai, M. Boyd, 2021, Thoracic cancer.

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

E. Van Cutsem, R. Kelley, C. Verslype, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospects and progress of atezolizumab in non-small cell lung cancer

Keunchil Park, J. Vansteenkiste, E. Wauters, 2017, Expert opinion on biological therapy.

Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

Y. Pritchett, A. Spira, J. Beck, 2021, Cancer management and research.

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

G. Sonpavde, M. Ernstoff, M. Carducci, 2014, Cancer.

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J. Burke, A. Eisen, M. Kohli, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation

S. Ramalingam, H. Borghaei, C. Barrios, 2020 .

Abstract CT011: NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC)

J. Blando, J. Mazières, Y. Zheng, 2022, Cancer Research.

Phase 1B Study of Momelotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated None—Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure

K. Kelly, D. Barbie, J. Kawashima, 2018, Clinical lung cancer.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

Suzanne F. Jones, B. Mahal, D. Gerber, 2021, Clinical Cancer Research.

First Results of Phase I/II Studies Evaluating Viral Vector-Based Heterologous Prime/Boost Immunotherapy Against Predicted HLA Class I Neoantigens Demonstrate CD8 T Cell Responses In Patients with Advanced Cancers

Adam R Ferguson, C. Drake, D. Carbone, 2019 .

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

N. Girard, Dohoung Kim, B. Cho, 2021 .

Differentiation therapy.

M. Carducci, A. Spira, 2020, Current opinion in pharmacology.

Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.

P. Hari, A. Nooka, A. Raptis, 2019, Journal of Clinical Oncology.

Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study

A. Tolcher, A. Bardia, T. Mukohara, 2022, Cancer Research.

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.

A. Jimeno, L. Nabell, D. Bowles, 2016, Clinical colorectal cancer.

Complete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets

J. Trepel, Min-Jung Lee, B. Oronsky, 2018, Clinical case reports.

MA03.02 TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors

R. Heist, F. Meric-Bernstam, K. Yoh, 2021, Journal of Thoracic Oncology.

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

Michael Thomas, Melissa L. Johnson, K. Yoh, 2021 .

Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.

R. Heist, K. Kelly, E. Vokes, 2019, Journal of Clinical Oncology.

Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy.

J. Christensen, C. Blakely, P. Olson, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial.

S. Gettinger, M. Ahn, E. Felip, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer.

Michael Thomas, E. Felip, S. Shreeve, 2021, Future Oncology.

Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry

R. Schilsky, J. Gralow, A. Jazieh, 2021, JCO oncology practice.

ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)

J. Radford, S. Horwitz, J. Wuerthner, 2019, Hematological Oncology.

LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021, Annals of Oncology.

O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021, Annals of Oncology.

LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial

A. Tolcher, A. Bardia, Toshio Shimizu, 2021 .

Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.

L. I. Hecker, A. Spira, A. Cohn, 2013, European journal of cancer.

LBA24 KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation

J. Christensen, S. Ou, R. Yaeger, 2022, Annals of Oncology.

Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial

A. Spira, L. Asmar, L. Gluck, 2013, Investigational New Drugs.

Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: Interim results from an ongoing phase 1 study.

G. Giaccone, G. Oxnard, A. Krivoshik, 2016 .

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Hung-Ming Wang, V. Lee, P. Lou, 2021, Clinical Cancer Research.

1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A

S. Oh, A. Spira, S. Kim, 2021, Annals of Oncology.

Clinical Trial Design in the Age of Molecular Profi ling

K. Edmiston, A. Spira, 2018 .

Clinical trial design in the age of molecular profiling.

K. Edmiston, A. Spira, 2012, Methods in molecular biology.

Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

David S. Shames, Matthew D. Hellmann, Garrett M. Frampton, 2016 .

Adagrasib in Non-Small-Cell Lung Cancer. Reply.

P. Jänne, A. Spira, J. Sabari, 2022, The New England journal of medicine.

Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC.

G. Giaccone, G. Oxnard, A. Krivoshik, 2015 .

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

S. Horwitz, J. Boni, A. Spira, 2017 .

CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).

F. Meric-Bernstam, P. LoRusso, J. Harding, 2020 .

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

J. Burke, J. Leonard, A. Krishnan, 2020 .

A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.

P. Moore, J. Wigginton, J. Strauss, 2018 .

436PDPreliminary safety and efficacy of rovalpituzumab tesirine in patients with delta-like protein 3-expressing advanced solid tumors

H. Beltran, F. Kaye, A. Mansfield, 2017 .

Patient‐reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose‐escalation study 1108

A. Gupta, Jingsong Zhang, P. O’Donnell, 2019, Cancer.

Characterization of NRG1 gene fusion events in solid tumors.

Edward S. Kim, S. Ou, J. Nieva, 2020 .

Title: Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer

Edward S. Kim, M. Socinski, Chul Kim, 2021 .

Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions

P. Jänne, J. Neal, Gregory Riely, 2019, Annals of Oncology.

Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.

Keunchil Park, J. Yi, J. Mazières, 2016 .

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

O. Vasiljeva, G. V. van Dongen, F. Meric-Bernstam, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors

Michael N. Alonso, E. Perez, D. Juric, 2021 .

An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC)

A. Spira, L. Asmar, R. Jotte, 2007 .

Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).

M. Socinski, E. Smit, V. Lee, 2022, Journal of Clinical Oncology.

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

G. Giaccone, G. Oxnard, A. Krivoshik, 2017, Clinical Cancer Research.

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

J. Burke, J. Leonard, A. Krishnan, 2019, Blood.

Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial

S. Gettinger, M. Ahn, R. Camidge, 2019, Annals of Oncology.

Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma

T. Powles, M. Ahn, M. Maio, 2018, Clinical Trials.

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

N. Girard, Keunchil Park, Dong-Wan Kim, 2020 .

43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

D. Waterhouse, E. Garon, A. Spira, 2022, Annals of Oncology.

620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion

R. Ramlau, E. Antonarakis, N. Vogelzang, 2021, Annals of Oncology.

Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

J. Powderly, A. Spira, D. Loo, 2021, Journal of Clinical Oncology.

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.

A. Spira, K. Marrone, S. Rosner, 2023, Future oncology.

P2.06-007 A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non–Small Cell Lung Cancer (NSCLC): Topic: Phase I/II Trials

P. Jänne, J. Neal, D. Costa, 2017 .

Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)

N. Iannotti, N. Gabrail, A. Spira, 2007 .

Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

H. Lenz, T. Bekaii-Saab, S. Mikhail, 2015 .

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

P. Jänne, S. Ou, R. Heist, 2020 .

Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling

J. Riess, S. Ou, J. Bendell, 2020, European Journal of Cancer.

Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.

David C. Smith, E. Schmidt, V. Borges, 2017 .

A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.

A. El-Khoueiry, H. Burris, P. Munster, 2021 .

Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.

J. Berlin, A. Tolcher, P. Janne, 2023, Journal of Clinical Oncology.

Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma

J. Radford, S. Horwitz, J. Wuerthner, 2018, Blood.

1231PDA STUDY OF HSP90 INHIBITOR AT13387 ALONE AND IN COMBINATION WITH CRIZOTINIB (CZT) IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC).

J. Soria, D. Camidge, D. Mahadevan, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.

D. Jäger, H. Wakelee, S. Ou, 2016 .

Seroreactivity of analogous antigenic epitopes in glycoprotein 120 expressed in HIV-1 subtypes A, B, C, and D.

D. Ho, N. Sewankambo, L. Brown, 1995, AIDS research and human retroviruses.

Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond.

J. Gray, A. Spira, D. Younan, 2023, Lung cancer.

AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).

M. Socinski, L. Paz-Ares, M. Nishio, 2021 .

P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC

Melissa L. Johnson, B. Cho, R. Meng, 2021 .

Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies.

R. Govindan, A. Mansfield, Y. Lou, 2020, Journal of Clinical Oncology.

MO01.32 CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation

S. Ramalingam, H. Borghaei, C. Barrios, 2021 .

Phase Ib study: Selective histone deacetylase (HDAC) inhibitor ACY-241 + nivolumab (Nivo) in advanced non-small cell lung cancer (NSCLC).

C. Dumitru, A. Spira, M. Awad, 2019, Journal of Clinical Oncology.

460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers

A. Tolcher, K. Jhaveri, A. Spira, 2022, Annals of Oncology.

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

S. Ou, R. Heist, J. Christensen, 2022, Journal of Clinical Oncology.

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer

A. Spira, Lina Asmar, L. Asmar, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.

P. LoRusso, A. El-Khoueiry, A. Naing, 2019, Journal of Clinical Oncology.

Innovations in Clinical Trial Design in the Era of Molecular Profiling.

E. Petricoin, J. Wulfkuhle, K. Edmiston, 2017, Methods in molecular biology.

Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.

J. Neal, Gregory Riely, D. Costa, 2019, Journal of Clinical Oncology.

TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021 .

Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).

C. Kyriakopoulos, D. Potvin, J. Christensen, 2018 .

A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer.

A. Das, N. Iannotti, N. Gabrail, 2012, Clinical lung cancer.

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.

L. Mileshkin, M. Friedlander, A. Spira, 2023, British Journal of Cancer.

P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer

L. Paz-Ares, W. Edenfield, F. Braiteh, 2019, International Journal of Gynecological Cancer.

539P Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study

A. Drilon, S. Ou, M. Ahn, 2020 .

P1.01-83 IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab

V. Velcheti, J. Mazières, J. Goldschmidt, 2018, Journal of Thoracic Oncology.

Results of a phase II study of single-agent sunitinib in elderly non-small cell lung cancer patients.

A. Spira, L. Asmar, W. L. Gluck, 2011, Journal of Clinical Oncology.

1309P ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC)

Melissa L. Johnson, O. Gardner, H. Gilbert, 2020, Annals of Oncology.

Phase I evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies

J. Powderly, A. Spira, A. Udyavar, 2019, Annals of Oncology.

DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).

J. Nieva, H. Borghaei, Y. Boumber, 2019, Journal of Clinical Oncology.

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy.

C. Blakely, S. Gadgeel, D. Waterhouse, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)

M. Hochmair, A. Spira, A. Panaccione, 2022, Annals of Oncology.

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation

R. Yaeger, T. Bekaii-Saab, A. Spira, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.

R. Heist, W. Edenfield, C. Li, 2016 .

A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

D. Camidge, K. Goto, S. Gadgeel, 2022, Journal of Clinical Oncology.

Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer

M. Socinski, J. Nieva, A. Wozniak, 2023, Frontiers in oncology.

971TiP Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)

A. Spira, H. Horinouchi, D. Peterson, 2022, Annals of Oncology.

1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)

P. Jänne, J. Neal, Gregory Riely, 2020 .

P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

P. Jänne, J. Neal, Gregory Riely, 2018, Journal of Thoracic Oncology.

Safety, tolerability, and pharmacokinetics of the OX40 agonist ABBV-368 in patients with advanced solid tumors.

A. Tolcher, M. Blaney, A. Patnaik, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

J. Radford, P. Zinzani, A. Stathis, 2019, Blood.

1689P Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials

M. Lacouture, B. Cho, A. Spira, 2021, Annals of Oncology.

Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC).

Aaron M. Newman, A. Shaw, S. Ou, 2016 .

P47.05 A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)

R. Heist, K. Yoh, A. Spira, 2021, Journal of Thoracic Oncology.

OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy

Duc Minh Nguyen, P. Jänne, J. Neal, 2021, Journal of Thoracic Oncology.

CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.

A. El-Khoueiry, H. Mamdani, A. Spira, 2020 .

Real‐world outcomes among patients with EGFR‐mutated non‐small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first‐line setting

A. Spira, R. Shenolikar, Ping Sun, 2023, Cancer medicine.

HSR22-124: Real-World Outcomes Among Patients With Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors Versus Immunotherapy With or Without Chemotherapy in First-line Setting

A. Spira, R. Shenolikar, P. Sun, 2022, Journal of the National Comprehensive Cancer Network.

Complete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets

J. Trepel, Min-Jung Lee, B. Oronsky, 2018, Clinical Case Reports.

Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.

T. Mok, S. Thongprasert, N. Iannotti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.

W. Edenfield, F. Braiteh, C. Li, 2016 .

First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non–small cell lung cancer (NSCLC).

P. Jänne, J. Neal, Gregory Riely, 2018 .

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

David C. Smith, E. Small, S. Srinivas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ) in the phase III ALTA-1L trial.

S. Gettinger, M. Ahn, D. Camidge, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Cellular targets of infection and route of viral dissemination following an intravaginal inoculation of SIV into rhesus macaques

D. Ho, Steven Wolinsky, R. Koup, 1998 .

Abstract P6-12-15: Efficacy results of a phase 1/2 study of glucocorticoid receptor (GR) antagonist mifepristone (MIFE) in combination with eribulin in GR-positive triple-negative breast cancer (TNBC)

R. Nanda, T. Pluard, J. O’Shaughnessy, 2017 .

Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer

G. Blumenthal, A. Spira, A. Deitz, 2020, Therapeutic Innovation & Regulatory Science.

Successful Endobronchial Resection of Obstructive Inflammatory Myofibroblastic Airway Tumor with Anaplastic Lymphoma Kinase (ALK) Positivity

A. Mahajan, S. Khandhar, A. Spira, 2017 .

Abstract P6-10-03: Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

A. Tolcher, A. Bardia, T. Mukohara, 2023, Cancer Research.

C. Rudin, A. Jimeno, J. Bauman, 2015, Oral oncology.

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

A. Tolcher, R. Heist, F. Meric-Bernstam, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

R. Salgia, P. Janne, B. Cho, 2021, Journal of Thoracic Oncology.

A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC).

L. Sequist, J. Nieva, F. Shepherd, 2016 .

TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy ± carboplatin in advanced/metastatic non-small cell lung cancer (mNSCLC).

H. Borghaei, K. Papadopoulos, A. Spira, 2023, Journal of Clinical Oncology.

Abstract PD13-08: PD13-08 Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC)

A. Bardia, T. Mukohara, D. Juric, 2023, Cancer Research.

Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors

T. Burns, R. Heist, Y. Murciano-Goroff, 2023, Cancer Research.

Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE).

Brian A. Chauder, J. Hecht, H. Lenz, 2022, Journal of Clinical Oncology.

OA03.03 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study

R. Heist, F. Meric-Bernstam, K. Yoh, 2021 .

TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).

A. Santin, A. Spira, K. Tse, 2023, Journal of Clinical Oncology.

A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.

W. Edenfield, F. Braiteh, C. Li, 2017 .

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases

P. Jänne, R. Heist, J. Christensen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MO01.42 Myelopreservation with Trilaciclib Regardless of Risk of Chemotherapy-Induced Febrile Neutropenia and/or Anemia or Red Blood Cell Transfusions

S. Gurubhagavatula, S. Morris, Y. Pritchett, 2021 .

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions

Jie Yang, M. Socinski, E. Smit, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).

Edward S. Kim, M. Socinski, Chul Kim, 2020 .

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

S. Ou, Keunchil Park, Dong-Wan Kim, 2023, Nature Medicine.

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial

V. Gopalakrishnan, V. Anagnostou, Y. Zheng, 2023, Cancer discovery.

Abstract CT032: Trials in progress: a global phase 1/1b clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma

A. Italiano, G. Long, S. Kato, 2023, Cancer Research.

MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study

R. Govindan, Keunchil Park, R. Salgia, 2022, Annals of Oncology.

2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma

J. Burke, A. Eisen, M. Kohli, 2015 .